1307740-93-7

Basic information

• Product Name: 2-(4-butylamino-3-methoxyphenyl)-1,1,1,3,3,3-hexafluoropropan-2-ol
• Synonyms: 2-(4-butylamino-3-methoxyphenyl)-1,1,1,3,3,3-hexafluoropropan-2-ol
• CAS NO: 1307740-93-7
• Molecular Weight: 345.285
• Mol File: 1307740-93-7.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: 2-(4-butylamino-3-methoxyphenyl)-1,1,1,3,3,3-hexafluoropropan-2-ol(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(4-butylamino-3-methoxyphenyl)-1,1,1,3,3,3-hexafluoropropan-2-ol(1307740-93-7)
• EPA Substance Registry System: 2-(4-butylamino-3-methoxyphenyl)-1,1,1,3,3,3-hexafluoropropan-2-ol(1307740-93-7)

Safety Data

• Hazardous Substances Data: 1307740-93-7(Hazardous Substances Data)

Upstream product

• 65570-20-9 butyl-(2-methoxy-phenyl)amine 
• 684-16-2 Hexafluoroacetone 

Downstream Products

• 1307741-06-5 N-butyl-N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)-2-methoxyphenyl]-2-iodobenzamide 
• 1307741-65-6 2-bromo-N-butyl-N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)-2-methoxyphenyl]-5-methoxybenzamide 

Relevant articles and documents

Structure-activity relationship-guided development of retinoic acid receptor-related orphan receptor gamma (RORγ)-selective inverse agonists with a phenanthridin-6(5H)-one skeleton from a liver X receptor ligand

Retinoic acid receptor-related orphan receptors (RORs), which belong to the nuclear receptor superfamily, regulate many physiological processes, including hepatic gluconeogenesis, lipid metabolism, immune function and circadian rhythm. Since RORs resemble liver X receptors (LXRs) in the fold structure of their ligand-binding domains, we speculated that ROR-mediated transcription might be modulated by LXR ligands, in line with the multi-template hypothesis. Therefore, we screened our LXR ligand library for compounds with ROR ligand activity and identified a novel ROR ligand with a phenanthridin-6(5H)-one skeleton. Structure-activity relationship studies aimed at separating ROR inverse agonistic activity from LXR-agonistic activity enabled us to develop a series of ROR inverse agonists based on the phenanthridin-6(5H)-one skeleton, including a RORγ-selective inverse agonist.